Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Atropisomerism by Design: Discovery of a Selective and Stable Phosphoinositide 3-Kinase (PI3K) β Inhibitor.

Chandrasekhar J, Dick R, Van Veldhuizen J, Koditek D, Lepist EI, McGrath ME, Patel L, Phillips G, Sedillo K, Somoza JR, Therrien J, Till NA, Treiberg J, Villaseñor AG, Zherebina Y, Perreault S.

J Med Chem. 2018 Aug 9;61(15):6858-6868. doi: 10.1021/acs.jmedchem.8b00797. Epub 2018 Jul 30.

PMID:
30015489
2.

Recent encounters with atropisomerism in drug discovery.

Glunz PW.

Bioorg Med Chem Lett. 2018 Jan 15;28(2):53-60. doi: 10.1016/j.bmcl.2017.11.050. Epub 2017 Dec 6. Review.

PMID:
29223590
3.

Atropisomerism in medicinal chemistry: challenges and opportunities.

Toenjes ST, Gustafson JL.

Future Med Chem. 2018 Feb;10(4):409-422. doi: 10.4155/fmc-2017-0152. Epub 2018 Jan 30.

PMID:
29380622
4.

Revealing atropisomer axial chirality in drug discovery.

LaPlante SR, Edwards PJ, Fader LD, Jakalian A, Hucke O.

ChemMedChem. 2011 Mar 7;6(3):505-13. doi: 10.1002/cmdc.201000485. Epub 2011 Jan 5.

PMID:
21360821
5.

The role of chromatographic and chiroptical spectroscopic techniques and methodologies in support of drug discovery for atropisomeric drug inhibitors of Bruton's tyrosine kinase.

Dai J, Wang C, Traeger SC, Discenza L, Obermeier MT, Tymiak AA, Zhang Y.

J Chromatogr A. 2017 Mar 3;1487:116-128. doi: 10.1016/j.chroma.2017.01.016. Epub 2017 Jan 6.

PMID:
28131592
6.

Phosphoinositide 3-kinase β, phosphoinositide 3-kinase δ, and phosphoinositide 3-kinase γ mediate the anti-inflammatory effects of magnesium sulfate.

Lee PY, Yang CH, Kao MC, Su NY, Tsai PS, Huang CJ.

J Surg Res. 2015 Aug;197(2):390-7. doi: 10.1016/j.jss.2015.04.051. Epub 2015 Apr 18.

PMID:
25972311
7.

Axial chirality of 4-arylpyrazolo[3,4-b]pyridines. Conformational analysis and absolute configuration.

Gunasekaran P, Perumal S, Menéndez JC, Mancinelli M, Ranieri S, Mazzanti A.

J Org Chem. 2014 Nov 21;79(22):11039-50. doi: 10.1021/jo502047n. Epub 2014 Nov 7.

PMID:
25330038
8.

Theoretical studies on beta and delta isoform-specific binding mechanisms of phosphoinositide 3-kinase inhibitors.

Zhu J, Pan P, Li Y, Wang M, Li D, Cao B, Mao X, Hou T.

Mol Biosyst. 2014 Mar 4;10(3):454-66. doi: 10.1039/c3mb70314b. Epub 2013 Dec 16.

PMID:
24336903
9.

Recent trends and applications in liquid-phase chromatography enantioseparation of atropisomers.

Peluso P, Mamane V, Aubert E, Cossu S.

Electrophoresis. 2017 Aug;38(15):1830-1850. doi: 10.1002/elps.201600502. Epub 2017 Feb 24. Review.

PMID:
28168709
10.

Induction of chirality: experimental evidence of atropisomerism in azapeptides.

Ottersbach PA, Schnakenburg G, Gütschow M.

Chem Commun (Camb). 2012 Jun 11;48(46):5772-4. doi: 10.1039/c2cc31161e. Epub 2012 May 2.

PMID:
22552375
11.

Biocatalytic Dynamic Kinetic Resolution for the Synthesis of Atropisomeric Biaryl N-Oxide Lewis Base Catalysts.

Staniland S, Adams RW, McDouall JJ, Maffucci I, Contini A, Grainger DM, Turner NJ, Clayden J.

Angew Chem Int Ed Engl. 2016 Aug 26;55(36):10755-9. doi: 10.1002/anie.201605486. Epub 2016 Aug 9.

PMID:
27504722
12.

Peptoid atropisomers.

Paul B, Butterfoss GL, Boswell MG, Renfrew PD, Yeung FG, Shah NH, Wolf C, Bonneau R, Kirshenbaum K.

J Am Chem Soc. 2011 Jul 20;133(28):10910-9. doi: 10.1021/ja2028684. Epub 2011 Jun 22.

PMID:
21634437
13.

Atropisomerism about Aryl-C(sp(3)) Bonds: Conformational Behavior of Substituted Phenylcyclohexanes in Solution.

Flos M, Lameiras P, Denhez C, Mirand C, Berber H.

J Org Chem. 2016 Mar 18;81(6):2372-82. doi: 10.1021/acs.joc.5b02856. Epub 2016 Mar 2.

PMID:
26906493
14.

Exploiting Atropisomerism to Increase the Target Selectivity of Kinase Inhibitors.

Smith DE, Marquez I, Lokensgard ME, Rheingold AL, Hecht DA, Gustafson JL.

Angew Chem Int Ed Engl. 2015 Sep 28;54(40):11754-9. doi: 10.1002/anie.201506085. Epub 2015 Aug 14.

PMID:
26276764
15.

Atropisomerism in a 10-Membered Ring with Multiple Chirality Axes: (3 Z,9 Z)-1,2,5,8-Dithiadiazecine-6,7(5 H,8 H)-dione Series.

Risso V, Farran D, Javierre G, Naubron JV, Giorgi M, Piras P, Jean M, Vanthuyne N, Fruttero R, Lorcy D, Roussel C.

J Org Chem. 2018 Aug 3;83(15):7566-7573. doi: 10.1021/acs.joc.8b01009. Epub 2018 Jun 13.

PMID:
29884018
16.

Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design.

Cheng H, Li C, Bailey S, Baxi SM, Goulet L, Guo L, Hoffman J, Jiang Y, Johnson TO, Johnson TW, Knighton DR, Li J, Liu KK, Liu Z, Marx MA, Walls M, Wells PA, Yin MJ, Zhu J, Zientek M.

ACS Med Chem Lett. 2012 Nov 7;4(1):91-7. doi: 10.1021/ml300309h. eCollection 2013 Jan 10.

17.

Atropisomerism and Conformational Equilibria: Impact on PI3Kδ Inhibition of 2-((6-Amino-9H-purin-9-yl)methyl)-5-methyl-3-(o-tolyl)quinazolin-4(3H)-one (IC87114) and Its Conformationally Restricted Analogs.

Lodola A, Bertolini S, Biagetti M, Capacchi S, Facchinetti F, Gallo PM, Pappani A, Mor M, Pala D, Rivara S, Visentini F, Corsi M, Capelli AM.

J Med Chem. 2017 May 25;60(10):4304-4315. doi: 10.1021/acs.jmedchem.7b00247. Epub 2017 May 15.

PMID:
28489362
18.

A novel signaling pathway for beta-adrenergic receptor-mediated activation of phosphoinositide 3-kinase in H9c2 cardiomyocytes.

Yano N, Ianus V, Zhao TC, Tseng A, Padbury JF, Tseng YT.

Am J Physiol Heart Circ Physiol. 2007 Jul;293(1):H385-93. Epub 2007 Mar 16.

19.

Specific function of phosphoinositide 3-kinase beta in the control of DNA replication.

Marqués M, Kumar A, Poveda AM, Zuluaga S, Hernández C, Jackson S, Pasero P, Carrera AC.

Proc Natl Acad Sci U S A. 2009 May 5;106(18):7525-30. doi: 10.1073/pnas.0812000106. Epub 2009 Apr 22.

Supplemental Content

Support Center